Immunovant (IMVT) PT Lowered to $24 at Truist Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Six killed in cyclone off India's eastern coast
- Qualcomm shares fall on Intel warning and legal concerns
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Sandisk announces 8-for-1 forward stock split effective November 2026
- Reddit, Inc. (RDDT) Tops Q3 EPS by 7c, Beats on Revenue; Offers Q4 Revenue Guidance
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Raymond James Downgrades Immunovant (IMVT) to Market Perform
June 1, 2021 3:31 PM EDTRaymond James analyst Danielle Brill downgraded Immunovant (NASDAQ: IMVT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.
Shares of Immunovant closed at $15.16 yesterday.
... MoreGuggenheim Downgrades Immunovant (IMVT) to Neutral
June 1, 2021 1:22 PM EDTGuggenheim analyst Yatin Suneja downgraded Immunovant (NASDAQ: IMVT) from Buy to Neutral.
For an analyst ratings summary and ratings history on Immunovant click here. For more ratings news on Immunovant click here.
Shares of Immunovant closed at $15.16 yesterday.
... MoreStifel Downgrades Immunovant (IMVT) to Hold
June 1, 2021 10:27 AM EDTStifel analyst Derek C. Archila downgraded Immunovant (NASDAQ: IMVT) from Buy to Hold with a price target of $9.00 (from $28.00).
The analyst commented, "This morning, IMVT provided an update indicating that IMVT-1401's LDL increases are due to the on-target reductions of albumin that... More



